title: [Analysis on prognosis and correlative factors of acute nonlymphocytic leukemia].
abstract: To analyze the prognosis and risk factors of acute nonlymphocytic leukemia (ANLL), 94 patients with acute nonlymphocytic leukemia were enrolled in this study, while survival rate and risk factors of prognosis were analyzed. The results indicated that the complete remission (CR) ratio was 51.1%. Overall survival and event-free survival rates of month 6, 12, 18, 24 were 68.6%, 55.8%, 53.8%, 46.4%, 21.3% and 57.9%, 38.6%, 33.3%, 31.6%, 0% respectively. The factors such as age<40 years, WBC<10.0x10(9)/L before chemotherapy, WBC in the period of bone marrow suppression<1.0x10(9)/L, chemotherapy within 1 month after occurrence of leukemia, blood transfusion before chemotherapy of APL had favourable influence on remission and survival rates of ANLL patients. CR1, the time to get CR, length of CR and relapse significantly correlated with prognosis (p<0.05). It is concluded that the individualized therapy concerning the risk factors should be applied to ANLL patients for improving the remission, survival rate and prognosis.
authors: Department of Hematology, The General Hospital, Tianjin Medical University, Tianjin 300052, China.
authors: Chun-Yan
authors: CY
authors: Liu
authors: Rong
authors: R
authors: Fu
authors: Wen-Hui
authors: WH
authors: Liu
authors: Yu-Qian
authors: YQ
authors: Cheng
authors: Wen-Xiu
authors: WX
authors: Song
authors: Li-Juan
authors: LJ
authors: DU
authors: Er-Bao
authors: EB
authors: Ruan
authors: Li-Tong
authors: LT
authors: Zhang
authors: Xiao-Ming
authors: XM
authors: Wang
authors: Yong
authors: Y
authors: Liang
authors: Guo-Jin
authors: GJ
authors: Wang
authors: Wen
authors: W
authors: Qu
authors: Jia
authors: J
authors: Song
authors: Rong-Li
authors: RL
authors: Zhang
authors: Jing
authors: J
authors: Guan
authors: Li-Juan
authors: LJ
authors: Li
authors: Yang
authors: Y
authors: Song
authors: Shan
authors: S
authors: Gao
authors: Hui
authors: H
authors: Liu
authors: Hui-Juan
authors: HJ
authors: Jiang
authors: Jun
authors: J
authors: Wang
authors: Peng
authors: P
authors: Zou
authors: Zong-Hong
authors: ZH
authors: Shao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006248:Harringtonines / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014212:Tretinoin / Q000008:administration & dosage / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D006248:Harringtonines; D003561:Cytarabine; C062500:harringtonin; D014212:Tretinoin